The funding will advance two precision TYK2 inhibitors into the clinic for multiple sclerosis, psoriasis and other severe autoimmune and neurologic conditions.New investors include Dementia Discovery Fund, Leaps by Bayer, and UPMC Enterprises.CARMEL, Ind. (BUSINESS WIRE) #TYK2 Sudo Biosciences (“Sudo”), a biophar.